

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

05 Jul 2026

### Investigating the effect of sulfate magnesium tablet on atrial fibrillation after coronary artery bypass grafting in Heshmat Hospital in 2019

#### Protocol summary

Cardiopulmonary bypass graft surgery, Hospitalization time in ICU and hospital

#### Study aim

Determination of the prophylactic role of magnesium tablets on reduction of atrial fibrillation rhythm in patients undergone coronary artery bypass graft surgery

#### Design

A randomized clinical trial, phase 3 with parallel groups, that includes a control group, design of 70 patients.

#### Settings and conduct

This study will be done at Heshmat Hospital in Rasht on patients undergoing Coronary artery bypass graft surgery. Seventy patients randomly and with quadruple block method will be divided in two groups of magnesium sulfate and control. Magnesium level of plasma will be controlled daily for both groups And if it was higher than normal, the medication will be discontinued for the intervention group. Patients who have arterial fibrillation(AF) rhythm in the monitor for more than 30 seconds are considered as AF+ patients. Finally, the data will be compared in 2 groups. This study does not require blindness and patients and the surgeon are aware of the process.

#### Participants/Inclusion and exclusion criteria

Inclusion Criteria: Only cardiopulmonary bypass graft surgery (not associated with valve operation). First-time open heart surgery. Ejection Fraction(EF) more than 35%. Non-inclusion Criteria: History of Previous arterial fibrillation(AF), History of kidney disease, History of showing an allergic reaction to magnesium, History of taking antiarrhythmic drugs.

#### Intervention groups

Intervention group: A 250 milligrams magnesium tablet (produced by the 21st-century company) will be prescribed daily from 48 hours before the operation. After the operation and transferred to ICU, if the patient is extubated, orally and if still intubated, through NGT tube, he will receive next doses till the fifth-day after the operation. The control group won't receive any drug.

#### Main outcome variables

Arterial fibrillation rhythm in patients undergoing

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20190413043252N1**

Registration date: **2019-05-18, 1398/02/28**

Registration timing: **prospective**

Last update: **2019-05-18, 1398/02/28**

Update count: **0**

##### Registration date

2019-05-18, 1398/02/28

##### Registrant information

##### Name

gholamreza kanani

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 13 3366 9066

##### Email address

dr\_kanani@gums.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2019-05-22, 1398/03/01

##### Expected recruitment end date

2020-05-21, 1399/03/01

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

**Trial completion date**

empty

**Scientific title**

Investigating the effect of sulfate magnesium tablet on atrial fibrillation after coronary artery bypass grafting in Heshmat Hospital in 2019

**Public title**

The effect of sulfate magnesium on atrial fibrillation after open heart surgery

**Purpose**

Prevention

**Inclusion/Exclusion criteria****Inclusion criteria:**

Only cardiopulmonary bypass graft surgery (not associated with valve operation). First-time open heart surgery Ejection Fraction(EF) more than 35%

**Exclusion criteria:**

History of Previous arterial fibrillation(AF) History of kidney disease History of taking magnesium and showing an allergic reaction History of taking antiarrhythmic drugs (such as amiodarone -digoxin -warfarin) Being pregnant Having a pacemaker AV BLOCK In the ECG

**Age**

No age limit

**Gender**

Both

**Phase**

3

**Groups that have been masked**

No information

**Sample size**

Target sample size: 70

**Randomization (investigator's opinion)**

Randomized

**Randomization description**

Patients will be selected based on inclusion criteria and then classified into two groups receiving magnesium sulfate and control group, using the random block method in quadruple blocks based on the obtained list. To generate random sequences in this clinical trial, <http://www.graphpad.com/quickcalcs/index.cfm> will be used.

**Blinding (investigator's opinion)**

Not blinded

**Blinding description****Placebo**

Not used

**Assignment**

Parallel

**Other design features****Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Ethics Committee Of Guilan University Of Medical Sciences

**Street address**

Vice Chancellor for research, Shahid Siadati Avenue, Namjoo Street

**City**

Rasht

**Province**

Guilan

**Postal code**

4144666949

**Approval date**

2019-03-09, 1397/12/18

**Ethics committee reference number**

IR.GUMS.REC.1397.493

**Health conditions studied****1****Description of health condition studied**

Atrial fibrillation and fluttery

**ICD-10 code**

شماره 148

**ICD-10 code description**

IX 100-199 Diseases of the circulatory system

**Primary outcomes****1****Description**

Effect on prevention of AF rhythm in patients with coronary artery bypass graft surgery

**Timepoint**

24-hour patient monitoring until the fifth day

**Method of measurement**

ECG monitoring

**Secondary outcomes****1****Description**

Reducing hospitalization time in the ICU and hospital, and thus reducing patient hospitalization costs

**Timepoint**

After patient's discharge from hospital

**Method of measurement**

Number of hospitalization days

**Intervention groups****1****Description**

Intervention group: All pre-operative patients will be interviewed and the method will be explained to them and written informed consent will be obtained. In both groups, a blood sample for magnesium serum will be

taken first and if it is within the normal range (1/5-2/5 milliequivalents per liter), from 48 hours pre-operation, a 250 milligrams magnesium tablet (manufacturer: 21st century) will be given to intervention group at 6 am. This step is done by a collaborator nurse. After surgery and transfer to the ICU, both groups of patients undergo intensive care and ECG monitoring. The intervention group, in case of staying intubated they will take the tablet through NGT tube and if extubated they will take it orally their next 6 am tablet and it will be continued till the fifth day after surgery. The nurse giving the drug to the patient is not in the care team. Magnesium level of plasma in both groups will be controlled daily and if it was higher than the normal range, the medication will be stopped. All this time, a collaborator anesthetist is aware of receiving the drug by intervention group and will intervene immediately in the event of a complication.

**Category**

Prevention

**2****Description**

Control group: This group does not receive any drug.

**Category**

Prevention

**Recruitment centers****1****Recruitment center****Name of recruitment center**

Heshmat Hospital

**Full name of responsible person**

Dr Gholamreza Kanani

**Street address**

Heshmat Hospital, at the beginning of bayani street, Mosalla Square

**City**

Rasht

**Province**

Guilan

**Postal code**

4144654839

**Phone**

+98 13 1666 9064

**Email**

heshmat@gums.ac.ir

**Sponsors / Funding sources****1****Sponsor****Name of organization / entity**

Rasht University of Medical Sciences

**Full name of responsible person**

Doctor Shadman Nemati

**Street address**

Vice Chancellor for research of Guilan, Shahid Siadati Avenue, Namjoo Street

**City**

Rasht

**Province**

Guilan

**Postal code**

4144666949

**Phone**

+98 13 3333 5821

**Fax**

+98 13 3333 6395

**Email**

drshadmannemati\_ent@yahoo.com

**Grant name****Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Rasht University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

*empty*

**Country of origin****Type of organization providing the funding**

Academic

**Person responsible for general inquiries****Contact****Name of organization / entity**

Rasht University of Medical Sciences

**Full name of responsible person**

Gholamreza Kanani

**Position**

Assistant Professor of Cardiology

**Latest degree**

Specialist

**Other areas of specialty/work**

Cardiology

**Street address**

Heshmat Hospital, at the beginning of bayani street, Mosalla Square

**City**

Rasht

**Province**

Guilan

**Postal code**

4144654839

**Phone**

+98 13 3366 9066

**Fax****Email**

dr\_kanani@gums.ac.ir

**Person responsible for scientific**

## **inquiries**

### **Contact**

**Name of organization / entity**

Rasht University of Medical Sciences

**Full name of responsible person**

Gholamreza Kanani

**Position**

Assistant Professor of Cardiology

**Latest degree**

Specialist

**Other areas of specialty/work**

Cardiology

**Street address**

Heshmat Hospital, at the beginning of bayani street, Mosalla Square

**City**

Rasht

**Province**

Guilan

**Postal code**

4144654839

**Phone**

+98 13 3366 9066

**Fax**

**Email**

dr\_kanani@gums.ac.ir

## **Person responsible for updating data**

### **Contact**

**Name of organization / entity**

Rasht University of Medical Sciences

**Full name of responsible person**

Mohadese Ahmadi

**Position**

Research Expert/(MSc) English

**Latest degree**

Master

### **Other areas of specialty/work**

Research Expert

### **Street address**

Anesthesiology Reseach Center, Alzahra Hospital, Namjoo Street

### **City**

Rasht

### **Province**

Guilan

### **Postal code**

4144654839

### **Phone**

+98 13 3336 9328

### **Email**

p.ahmadi2311@gmail.com

## **Sharing plan**

### **Deidentified Individual Participant Data Set (IPD)**

Undecided - It is not yet known if there will be a plan to make this available

### **Study Protocol**

Undecided - It is not yet known if there will be a plan to make this available

### **Statistical Analysis Plan**

Undecided - It is not yet known if there will be a plan to make this available

### **Informed Consent Form**

Undecided - It is not yet known if there will be a plan to make this available

### **Clinical Study Report**

Undecided - It is not yet known if there will be a plan to make this available

### **Analytic Code**

Undecided - It is not yet known if there will be a plan to make this available

### **Data Dictionary**

Undecided - It is not yet known if there will be a plan to make this available